There could be more at stake for Pfizer in its UK Supreme Court pregabalin patent dispute than was previously thought. A recently-released study argues that if the pharma company loses the case, it will be liable to pay the National Health Service (NHS) £502 million in compensation.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Being a charter subscriber of IAM, I have found useful articles in every issue from the beginning. I like the variety in the subject matter and the depth at which most articles explore. Your ability to attract the best practitioners of IAM to submit articles keeps the quality and usefulness of your publication at a consistently high level.

Bruce Story
Senior advisor
ipCapital Group (ipCG)


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?